OBJECTIVES: To assess the effects of amifostine on salivary glands in radioactive iodine-treated differentiated thyroid cancer. METHODS: We searched the MEDLINE, EMBASE and the Cochrane Library for randomized controlled clinical trials which compared the effects of amifostine with those of placebo or acid-stimulating agents. RESULTS: Two randomized controlled clinical trials with a total of 130 patients were included. Both studies had a low risk of bias. There were no statistically significant differences between the effects of amifostine and acid-stimulating agents on the incidence of xerostomia (RR 0.24, 95% CI 0.01 to 9.52), the decrease of scintigraphically measured uptake of (99m)Tc by the parotid (RR 0.30, 95% CI -2.28 to 2.88) or submandibular glands (RR 1.90, 95% CI -1.46 to 5.26) at 12 months, or the reduction in blood pressure (RR 5.00, 95% CI 0.25 to 99.16). Neither of the included trials investigated death from any cause, morbidity, health-related quality of life or costs. CONCLUSION: The results of two randomized controlled clinical trials suggest that amifostine has no significant radioprotective effects on salivary glands in radioactive iodine treatment of differentiated thyroid cancer. The use of acid-stimulating agents to increase salivation should remain the first choice during radioactive iodine treatment of differentiated thyroid cancer. Patients should also be well informed of the importance of hydration and acid stimulation.
OBJECTIVES: To assess the effects of amifostine on salivary glands in radioactive iodine-treated differentiated thyroid cancer. METHODS: We searched the MEDLINE, EMBASE and the Cochrane Library for randomized controlled clinical trials which compared the effects of amifostine with those of placebo or acid-stimulating agents. RESULTS: Two randomized controlled clinical trials with a total of 130 patients were included. Both studies had a low risk of bias. There were no statistically significant differences between the effects of amifostine and acid-stimulating agents on the incidence of xerostomia (RR 0.24, 95% CI 0.01 to 9.52), the decrease of scintigraphically measured uptake of (99m)Tc by the parotid (RR 0.30, 95% CI -2.28 to 2.88) or submandibular glands (RR 1.90, 95% CI -1.46 to 5.26) at 12 months, or the reduction in blood pressure (RR 5.00, 95% CI 0.25 to 99.16). Neither of the included trials investigated death from any cause, morbidity, health-related quality of life or costs. CONCLUSION: The results of two randomized controlled clinical trials suggest that amifostine has no significant radioprotective effects on salivary glands in radioactive iodine treatment of differentiated thyroid cancer. The use of acid-stimulating agents to increase salivation should remain the first choice during radioactive iodine treatment of differentiated thyroid cancer. Patients should also be well informed of the importance of hydration and acid stimulation.
Authors: K H Bohuslavizki; S Klutmann; L Jenicke; S Kröger; R Buchert; J Mester; M Clausen Journal: Cancer Biother Radiopharm Date: 1999-10 Impact factor: 3.099
Authors: K H Bohuslavizki; W Brenner; S Lassmann; S Tinnemeyer; G Tönshoff; C Sippel; H Wolf; M Clausen; E Henze Journal: Nucl Med Commun Date: 1996-08 Impact factor: 1.690
Authors: K H Bohuslavizki; S Klutmann; W Brenner; S Kröger; R Buchert; C Bleckmann; J Mester; E Henze; M Clausen Journal: Strahlenther Onkol Date: 1999-11 Impact factor: 3.621
Authors: K H Bohuslavizki; W Brenner; S Lassmann; S Tinnemeyer; S Kalina; M Clausen; E Henze Journal: Nuklearmedizin Date: 1997-04 Impact factor: 1.379
Authors: Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita Journal: Thyroid Date: 2015-07 Impact factor: 6.568
Authors: F Brozzi; T Rago; W Bencivelli; F Bianchi; P Santini; P Vitti; A Pinchera; C Ceccarelli Journal: J Endocrinol Invest Date: 2012-04-05 Impact factor: 4.256
Authors: Joanna Klubo-Gwiezdzinska; John Costello; Kirk Jensen; Aneeta Patel; Rok Tkavc; Douglas Van Nostrand; Kenneth D Burman; Leonard Wartofsky; Vasyl Vasko Journal: Endocr Connect Date: 2017-08-08 Impact factor: 3.335